Johnson & Johnson's earnings call for Q2 2021 revealed strong financial performance, beating expectations across all segments with significant growth compared to both the previous year and 2019. The company reported robust sales and earnings, supported by recovery in medical procedures, strong pharmaceutical sales, and continued consumer health momentum. Management provided positive guidance for the remainder of 2021, indicating confidence in sustained growth backed by solid cash flow and strategic investments. The positive tone and strong performance relative to peers suggest a short-term positive impact on the stock.
[1]